Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Current Drug Therapy

Insulin treatment for type 2 diabetes: When to start, which to use

Marwan Hamaty, MD, MBA
Cleveland Clinic Journal of Medicine May 2011, 78 (5) 332-342; DOI: https://doi.org/10.3949/ccjm.78a.10051
Marwan Hamaty
Department of Endocrinology, Diabetes, and Metabolism, Diabetes Center, Endocrine and Metabolism Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In type 2 diabetes mellitus, oral hypoglycemic agents and analogues of glucagon-like peptide-1 provide adequate glycemic control early in the disease. Insulin therapy becomes necessary for those with advanced disease. Further, some experts recommend electively starting insulin therapy in early diabetes. This review addresses practical approaches to insulin therapy, particularly when it is indicated and which regimen to use.

Footnotes

  • ↵* The author has disclosed that he has been a reviewer for Eli Lilly and is a principal investigator in the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial, funded by Sanofi-Aventis.

  • Copyright © 2011 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 78 (5)
Cleveland Clinic Journal of Medicine
Vol. 78, Issue 5
1 May 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Insulin treatment for type 2 diabetes: When to start, which to use
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Insulin treatment for type 2 diabetes: When to start, which to use
Marwan Hamaty
Cleveland Clinic Journal of Medicine May 2011, 78 (5) 332-342; DOI: 10.3949/ccjm.78a.10051

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Insulin treatment for type 2 diabetes: When to start, which to use
Marwan Hamaty
Cleveland Clinic Journal of Medicine May 2011, 78 (5) 332-342; DOI: 10.3949/ccjm.78a.10051
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin
  • Clinical Insights Into a New, Disposable Insulin Delivery Device
  • Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
  • Google Scholar

More in this TOC Section

  • Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
  • A practical guide for buprenorphine initiation in the primary care setting
Show more Current Drug Therapy

Similar Articles

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire